Evaluating trastuzumab deruxtecan in patients with gastrooesophageal adenocarcinoma who are ctDNA and HER2 positive: DECIPHER

E. Smyth; D. Griffiths; K. Cozens; S. Ewings; R. Waugh; R.C. Turkington; K. Foley; R. Roy; S. Ngan; R. Owen; D. Chuter; C. Steele; G. Griffiths

doi:10.1016/j.esmogo.2024.100114

Evaluating trastuzumab deruxtecan in patients with gastrooesophageal adenocarcinoma who are ctDNA and HER2 positive: DECIPHER

E. Smyth^*
, D. Griffiths
, K. Cozens
, S. Ewings
, R. Waugh
, R.C. Turkington
, K. Foley
, R. Roy
, S. Ngan
, R. Owen
, D. Chuter
, C. Steele
, G. Griffiths

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

2 Downloads (Pure)

Original language	English
Article number	100114
Number of pages	8
Journal	ESMO gastrointestinal oncology
Volume	6
Early online date	28 Nov 2024
DOIs	https://doi.org/10.1016/j.esmogo.2024.100114
Publication status	Published - Dec 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Gastric cancer
ctDNA
Her2
Oesophageal Cancer
Minimal Residual Disease
Gastrooesophageal Adenocarcinoma

Access to Document

10.1016/j.esmogo.2024.100114Licence: CC BY

Evaluating trastuzumab deruxtecan in patients with gastrooesophageal adenocarcinoma who are ctDNA and HER2 positive: DECIPHER
Copyright 2024 the authors. This is an open access article published under a Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/.), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
Final published version, 461 KBLicence: CC BY

Cite this

Smyth, E., Griffiths, D., Cozens, K., Ewings, S., Waugh, R., Turkington, R. C., Foley, K., Roy, R., Ngan, S., Owen, R., Chuter, D., Steele, C., & Griffiths, G. (2024). Evaluating trastuzumab deruxtecan in patients with gastrooesophageal adenocarcinoma who are ctDNA and HER2 positive: DECIPHER. ESMO gastrointestinal oncology, 6, Article 100114. https://doi.org/10.1016/j.esmogo.2024.100114

@article{96fa9f78c6be42699e4d13531cff46ee,

title = "Evaluating trastuzumab deruxtecan in patients with gastrooesophageal adenocarcinoma who are ctDNA and HER2 positive: DECIPHER",

keywords = "Gastric cancer, ctDNA, Her2, Oesophageal Cancer, Minimal Residual Disease, Gastrooesophageal Adenocarcinoma",

author = "E. Smyth and D. Griffiths and K. Cozens and S. Ewings and R. Waugh and R.C. Turkington and K. Foley and R. Roy and S. Ngan and R. Owen and D. Chuter and C. Steele and G. Griffiths",

year = "2024",

month = dec,

doi = "10.1016/j.esmogo.2024.100114",

language = "English",

volume = "6",

journal = "ESMO gastrointestinal oncology",

issn = "2949-8198",

publisher = "Elsevier B.V.",

}

Smyth, E, Griffiths, D, Cozens, K, Ewings, S, Waugh, R, Turkington, RC, Foley, K, Roy, R, Ngan, S, Owen, R, Chuter, D, Steele, C & Griffiths, G 2024, 'Evaluating trastuzumab deruxtecan in patients with gastrooesophageal adenocarcinoma who are ctDNA and HER2 positive: DECIPHER', ESMO gastrointestinal oncology, vol. 6, 100114. https://doi.org/10.1016/j.esmogo.2024.100114

TY - JOUR

T1 - Evaluating trastuzumab deruxtecan in patients with gastrooesophageal adenocarcinoma who are ctDNA and HER2 positive: DECIPHER

AU - Smyth, E.

AU - Griffiths, D.

AU - Cozens, K.

AU - Ewings, S.

AU - Waugh, R.

AU - Turkington, R.C.

AU - Foley, K.

AU - Roy, R.

AU - Ngan, S.

AU - Owen, R.

AU - Chuter, D.

AU - Steele, C.

AU - Griffiths, G.

PY - 2024/12

Y1 - 2024/12

KW - Gastric cancer

KW - ctDNA

KW - Her2

KW - Oesophageal Cancer

KW - Minimal Residual Disease

KW - Gastrooesophageal Adenocarcinoma

U2 - 10.1016/j.esmogo.2024.100114

DO - 10.1016/j.esmogo.2024.100114

M3 - Article

SN - 2949-8198

VL - 6

JO - ESMO gastrointestinal oncology

JF - ESMO gastrointestinal oncology

M1 - 100114

ER -